CLINICAL TRIAL
ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Photodynamic therapy with indocyanine green for choroidal neovascularization caused by age-related macular degeneration--a preliminary record].

PURPOSE: To evaluate the usefulness of indocyanine green in the photodynamic therapy (iPDT) of choroidal neovascularization (CNV) in age-related macular degeneration (AMD).

MATERIAL AND METHODS: Twelve patients with choroidal neovascularization secondary to AMD were treated with iPDT. Therapy was performed with 810 nm diode laser after intravenous injection of 25 mg solution of indocyanine green. Within 3 months follow-up two visits were performed with ICGA images evaluation, at each control.

RESULTS: After therapy complete regression of the CNV was demonstrated by ICGA in 3 cases, partial regression was found in 5 patients, 3 revealed no changes and in one case the progression of the CNV was noted in spite of the treatment. Six patients presented increase in visual acuity, in 5 no changes were observed, and in one case a 2-line decrease in VA was detected by 3 months of follow-up.

CONCLUSIONS: Our preliminary study suggests that ICG mediated PDT can be a new and promising way, to treat neovascular AMD.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app